Key Market Insights
Presently, close to 50 gene switch platforms are being developed for various applications in adoptive cell therapies (ACT), including CAR-Ts, TCRs and gene therapies; majority of them are protein-based gene switches
Various small molecules, including rimiducid, rapamycin and dasatinib, are being investigated to design safety switch for ACTs; management of treatment related toxicity has emerged as the key application of such platforms
